Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures

Lidan Chang,Dandan Liu,Xuyan Zhao,Luyao Dai,Xueting Ren,Qian Hao,Peinan Liu,Hao Wu,Xiaobin Ma,Huafeng Kang

Clinical and Translational Oncology（2024）

引用 0|浏览7
暂无评分
关键词
T1 HER2-positive breast cancer,Neoadjuvant systemic therapy,Survival,Prognosis,Subgroup analysis
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要